Clinical Trial Update: A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating garetosmab versus placebo in adults with Fibrodysplasia Ossificans Progressiva; the study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrodysplasia Ossificans Progressiva

Drugs mentioned

• Garetosmab (Garetosmab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Fibrodysplasia Ossificans Progressiva | Phase 3 | Status: ACTIVE_NOT_RECRUITING